Showing results (91-100 of 116) with videos related to
Sort By:
Pageof 12
The American Journal of Managed Care|September 16, 2021
Association of the MedWise Risk Score with health care outcomesVeronique Michaud, Matt K Smith, Ravil Bikmetov, et al.European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|January 3, 2024
Exploring the impact of CYP2D6 and UGT2B7 gene-drug interactions, and CYP-mediated DDI on oxycodone and oxymorphone pharmacokinetics using physiologically-based pharmacokinetic modeling and simulationMarian Klose, Rodrigo Cristofoletti, Carolina de Miranda Silva, et al.Clinical and Translational Science|March 31, 2021
Adverse drug event risk assessment by the virtual addition of COVID-19 repurposed drugs to Medicare and commercially insured patients' drug regimens: A drug safety simulation studyMatt K Smith, Ravil Bikmetov, Sweilem B Al Rihani, et al.Drugs & Aging|November 9, 2021
Quantifying Anticholinergic Burden and Sedative Load in Older Adults with Polypharmacy: A Systematic Review of Risk Scales and ModelsSweilem B Al Rihani, Malavika Deodhar, Lucy I Darakjian, et al.Medicina (Kaunas, Lithuania)|January 21, 2023
Case Report: Performing a Medication Safety Review Assisted by Pharmacogenomics to Explain a Prescribing Cascade Resulting in a Patient FallJoshua Russell, Meghan J Arwood, Nicole M Del Toro-Pagán, et al.Journal of Patient Safety|May 17, 2021
Longitudinal Association of a Medication Risk Score With Mortality Among Ambulatory Patients Acquired Through Electronic Health Record DataAmanda Rondinelli Ratigan, Veronique Michaud, Jacques Turgeon, et al.Pharmaceutics|September 5, 2019
Impact of GSTA1 Polymorphisms on Busulfan Oral Clearance in Adult Patients Undergoing Hematopoietic Stem Cell TransplantationVeronique Michaud, My Tran, Benoit Pronovost, et al.Therapeutic Drug Monitoring|December 14, 2006
Inhibitory effects of propafenone on the pharmacokinetics of caffeine in humansVéronique Michaud, Mohamad Samer Mouksassi, Line Labbé, et al.Expert Opinion on Drug Safety|November 28, 2025
CYP450 activity, drug interactions, and genetic polymorphisms: clinical relevance for the new selective cardiac myosin inhibitorsMilind Y Desai, Veronique Michaud, David Thacker, et al.Journal of Population Therapeutics and Clinical Pharmacology = Journal De La Therapeutique Des Populations Et De La Pharmacologie Clinique|November 12, 2013
Clinical practice guideline: CYP2D6 genotyping for safe and efficacious codeine therapyParvaz Madadi, Ursula Amstutz, Michael Rieder, et al.Pageof 12